PNAS带来减肥新武器——一种口服液态盐

2019-12-01 佚名 中国生物技术网

肥胖正在困扰着许许多多的人,它不仅仅是体重增加、身材走样这么简单,还是多种常见疾病的驱动因素,如高血压、糖尿病、哮喘、中风和充血性心力衰竭。如今,肥胖已成为最严重的公共健康威胁之一。

肥胖正在困扰着许许多多的人,它不仅仅是体重增加、身材走样这么简单,还是多种常见疾病的驱动因素,如高血压糖尿病、哮喘、中风和充血性心力衰竭。如今,肥胖已成为最严重的公共健康威胁之一。

虽然遗传因素发挥了作用,但食用富含碳水化合物和脂肪的高热量食物是导致这种流行病的主要原因,尽管医生和营养学家推荐健康、均衡的饮食作为预防策略,但仍有很多人无法管住自己的嘴。

在过去几十年中,美国食品和药物管理局(FDA)已经批准了几种能够减轻体重约10%的减肥药,但它们都具有明显的副作用,包括头痛、腹泻、严重的肝损伤、出生缺陷、睡眠呼吸暂停、胰腺炎,甚至会导致自杀的想法。

近日,美国哈佛大学Wyss生物启发工程研究所和John A. Paulson工程与应用科学学院(SEAS)的一项新研究发现,一种口服液态盐,即胆碱和香叶酸离子液体(CAGE)可以降低人体对脂肪的吸收,而且大鼠实验证明,它没有明显的副作用,并且可将总体重降低约12%。该研究近日已发表在《PNAS》上。

研究第一作者、前Wyss研究所博士后研究员、德克萨斯大学药物科学助理教授Md Nurunnabi博士说:“减轻12%的体重就像一个人从200磅降到176,这是一个巨大的变化。我们的目标是将这项工作转化成一种产品,帮助人们保持更健康的体重。我们的研究标志着这一过程的开始。”

将“问题”转化为“方法”

CAGE是一种液态盐,是几年前由Wyss Core学院生物工程教授Samir Mitragotri开发的,目的是改善人体对药物的吸收。去年,他的实验室发表了一篇论文,描述了口服CAGE能够增强胰岛素吸收的能力。然而,在研究CAGE的性质时,他们发现有一种小型疏水分子不受CAGE的影响。 Mitragotri的团队预感CAGE会以某种方式与该分子结合并阻止其被吸收。

Mitragotri说:“这一观察让我们想知道,是否存在某种情况需要防止这种分子的吸收。 我们意识到脂肪很小且疏水,因此CAGE可能会成为治疗肥胖症的潜在药物。”

然后,研究人员通过将CAGE与称为DHA的omega-3脂肪混合在一起来评估CAGE与脂肪的相互作用。他们观察到DHA形成了大约3-4微米长的大颗粒,大约相当于细胞核的大小。仅与水混合的DHA分子形成了尺寸大小在50-400纳米范围内的更小颗粒。这表明CAGE与DHA分子之间存在某种相互作用,导致它们聚集为更大的颗粒。

然后,研究团队将DHA与CAGE混合物喂食健康大鼠。与仅注射DHA的大鼠肠道相比,在六个小时的过程中,CAGE的加入显着降低了DHA在肠组织中的渗透。

对抗肥胖

为了评估CAGE在活体动物中的作用,研究人员用DHA与CAGE的混合物制成的胶囊喂食大鼠。六小时后,动物血液中DHA的吸收量仅为只给予DHA大鼠的一半。生物分布研究表明,将CAGE与DHA一起使用会使其在和肠中的浓度增加两倍,并减少其在肝脏中的含量,这表明CAGE可以阻止DHA离开肠道

然后,研究团队分析了CAGE对高脂饮食大鼠脂肪摄取的影响,这种饮食比常规饮食高20%的脂肪,持续30天。每天服用10微升CAGE的大鼠体重比服用5微升或不服用CAGE的减少了约12%的体重。未服用CAGE的大鼠通常每天吃约10克的食物,而服用大剂量CAGE的大鼠则吃约8克的食物,这表明CAGE也可能对调节消化的酶有影响,增加了饱腹感。

更重要的是,在30天的时间内,服用CAGE的大鼠未出现副作用,并且没有发炎的迹象或者动物器官结构或功能的差异,而且治疗后体内也没有任何CAGE成分的迹象。

Mitragotri说:“这是一个概念证明研究,口服液态盐可以帮助减少脂肪摄入和减少体重,考虑到这种方法比吸脂或减肥手术更加简单、快速且侵入性小,因此它有巨大的临床潜力,并且它的作用机理是物理的,而不是化学的,它不会造成像其他药物所引起的副作用。”

该团队现在正在寻找与CAGE机制相关的更多答案,包括CAGE如何与脂肪结合、作用持续多长时间、它与肥胖相关的瘦素信号途径的潜在相互作用,以及未被吸收的脂肪流向了哪里。

Wyss研究所的创始董事、哈佛医学院和波士顿儿童医院的血管生物学教授Donald Ingber博士说:“这项研究是潜在转化性创新的完美示例,这些创新可能来自实验室中被视为解决方案而非问题的意外结果。我们喜欢这种简单的解决方案。”

原始出处:
Md Nurunnabi, Kelly N Ibsen,Samir Mitragotri,et al.Oral Ionic Liquid for the Treatment of Diet-Induced Obesity .Proc Natl Acad Sci U S A .2019 Nov 25.PMID: 31767747 DOI: 10.1073/pnas.1914426116

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1981155, encodeId=513d198115519, content=<a href='/topic/show?id=1bbe38225a4' target=_blank style='color:#2F92EE;'>#口服液#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38225, encryptionId=1bbe38225a4, topicName=口服液)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=856b247, createdName=songbq, createdTime=Sat Mar 07 23:27:00 CST 2020, time=2020-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1856366, encodeId=83c1185636605, content=<a href='/topic/show?id=f32014428fc' target=_blank style='color:#2F92EE;'>#PNAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14428, encryptionId=f32014428fc, topicName=PNAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Wed Jan 01 09:27:00 CST 2020, time=2020-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1048288, encodeId=9f16104828831, content=什么时候有懒人用的减肥神药?, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Sun Dec 01 18:27:00 CST 2019, time=2019-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376082, encodeId=42b33e608258, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Sun Dec 01 16:47:46 CST 2019, time=2019-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376081, encodeId=47b03e60818b, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Sun Dec 01 16:47:43 CST 2019, time=2019-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376080, encodeId=68a73e60805d, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Sun Dec 01 16:47:40 CST 2019, time=2019-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376079, encodeId=5ea53e607907, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Sun Dec 01 16:47:35 CST 2019, time=2019-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376078, encodeId=f59d3e6078fd, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Sun Dec 01 16:47:31 CST 2019, time=2019-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376077, encodeId=00603e6077be, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Sun Dec 01 16:47:29 CST 2019, time=2019-12-01, status=1, ipAttribution=)]
    2020-03-07 songbq
  2. [GetPortalCommentsPageByObjectIdResponse(id=1981155, encodeId=513d198115519, content=<a href='/topic/show?id=1bbe38225a4' target=_blank style='color:#2F92EE;'>#口服液#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38225, encryptionId=1bbe38225a4, topicName=口服液)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=856b247, createdName=songbq, createdTime=Sat Mar 07 23:27:00 CST 2020, time=2020-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1856366, encodeId=83c1185636605, content=<a href='/topic/show?id=f32014428fc' target=_blank style='color:#2F92EE;'>#PNAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14428, encryptionId=f32014428fc, topicName=PNAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Wed Jan 01 09:27:00 CST 2020, time=2020-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1048288, encodeId=9f16104828831, content=什么时候有懒人用的减肥神药?, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Sun Dec 01 18:27:00 CST 2019, time=2019-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376082, encodeId=42b33e608258, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Sun Dec 01 16:47:46 CST 2019, time=2019-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376081, encodeId=47b03e60818b, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Sun Dec 01 16:47:43 CST 2019, time=2019-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376080, encodeId=68a73e60805d, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Sun Dec 01 16:47:40 CST 2019, time=2019-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376079, encodeId=5ea53e607907, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Sun Dec 01 16:47:35 CST 2019, time=2019-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376078, encodeId=f59d3e6078fd, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Sun Dec 01 16:47:31 CST 2019, time=2019-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376077, encodeId=00603e6077be, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Sun Dec 01 16:47:29 CST 2019, time=2019-12-01, status=1, ipAttribution=)]
    2020-01-01 drwjr
  3. [GetPortalCommentsPageByObjectIdResponse(id=1981155, encodeId=513d198115519, content=<a href='/topic/show?id=1bbe38225a4' target=_blank style='color:#2F92EE;'>#口服液#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38225, encryptionId=1bbe38225a4, topicName=口服液)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=856b247, createdName=songbq, createdTime=Sat Mar 07 23:27:00 CST 2020, time=2020-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1856366, encodeId=83c1185636605, content=<a href='/topic/show?id=f32014428fc' target=_blank style='color:#2F92EE;'>#PNAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14428, encryptionId=f32014428fc, topicName=PNAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Wed Jan 01 09:27:00 CST 2020, time=2020-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1048288, encodeId=9f16104828831, content=什么时候有懒人用的减肥神药?, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Sun Dec 01 18:27:00 CST 2019, time=2019-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376082, encodeId=42b33e608258, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Sun Dec 01 16:47:46 CST 2019, time=2019-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376081, encodeId=47b03e60818b, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Sun Dec 01 16:47:43 CST 2019, time=2019-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376080, encodeId=68a73e60805d, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Sun Dec 01 16:47:40 CST 2019, time=2019-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376079, encodeId=5ea53e607907, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Sun Dec 01 16:47:35 CST 2019, time=2019-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376078, encodeId=f59d3e6078fd, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Sun Dec 01 16:47:31 CST 2019, time=2019-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376077, encodeId=00603e6077be, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Sun Dec 01 16:47:29 CST 2019, time=2019-12-01, status=1, ipAttribution=)]
    2019-12-01 CHANGE

    什么时候有懒人用的减肥神药?

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1981155, encodeId=513d198115519, content=<a href='/topic/show?id=1bbe38225a4' target=_blank style='color:#2F92EE;'>#口服液#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38225, encryptionId=1bbe38225a4, topicName=口服液)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=856b247, createdName=songbq, createdTime=Sat Mar 07 23:27:00 CST 2020, time=2020-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1856366, encodeId=83c1185636605, content=<a href='/topic/show?id=f32014428fc' target=_blank style='color:#2F92EE;'>#PNAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14428, encryptionId=f32014428fc, topicName=PNAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Wed Jan 01 09:27:00 CST 2020, time=2020-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1048288, encodeId=9f16104828831, content=什么时候有懒人用的减肥神药?, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Sun Dec 01 18:27:00 CST 2019, time=2019-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376082, encodeId=42b33e608258, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Sun Dec 01 16:47:46 CST 2019, time=2019-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376081, encodeId=47b03e60818b, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Sun Dec 01 16:47:43 CST 2019, time=2019-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376080, encodeId=68a73e60805d, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Sun Dec 01 16:47:40 CST 2019, time=2019-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376079, encodeId=5ea53e607907, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Sun Dec 01 16:47:35 CST 2019, time=2019-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376078, encodeId=f59d3e6078fd, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Sun Dec 01 16:47:31 CST 2019, time=2019-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376077, encodeId=00603e6077be, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Sun Dec 01 16:47:29 CST 2019, time=2019-12-01, status=1, ipAttribution=)]
    2019-12-01 14794e5bm67(暂无昵称)

    学习了,谢谢分享

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1981155, encodeId=513d198115519, content=<a href='/topic/show?id=1bbe38225a4' target=_blank style='color:#2F92EE;'>#口服液#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38225, encryptionId=1bbe38225a4, topicName=口服液)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=856b247, createdName=songbq, createdTime=Sat Mar 07 23:27:00 CST 2020, time=2020-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1856366, encodeId=83c1185636605, content=<a href='/topic/show?id=f32014428fc' target=_blank style='color:#2F92EE;'>#PNAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14428, encryptionId=f32014428fc, topicName=PNAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Wed Jan 01 09:27:00 CST 2020, time=2020-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1048288, encodeId=9f16104828831, content=什么时候有懒人用的减肥神药?, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Sun Dec 01 18:27:00 CST 2019, time=2019-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376082, encodeId=42b33e608258, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Sun Dec 01 16:47:46 CST 2019, time=2019-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376081, encodeId=47b03e60818b, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Sun Dec 01 16:47:43 CST 2019, time=2019-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376080, encodeId=68a73e60805d, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Sun Dec 01 16:47:40 CST 2019, time=2019-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376079, encodeId=5ea53e607907, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Sun Dec 01 16:47:35 CST 2019, time=2019-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376078, encodeId=f59d3e6078fd, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Sun Dec 01 16:47:31 CST 2019, time=2019-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376077, encodeId=00603e6077be, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Sun Dec 01 16:47:29 CST 2019, time=2019-12-01, status=1, ipAttribution=)]
    2019-12-01 14794e5bm67(暂无昵称)

    学习了,谢谢分享

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1981155, encodeId=513d198115519, content=<a href='/topic/show?id=1bbe38225a4' target=_blank style='color:#2F92EE;'>#口服液#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38225, encryptionId=1bbe38225a4, topicName=口服液)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=856b247, createdName=songbq, createdTime=Sat Mar 07 23:27:00 CST 2020, time=2020-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1856366, encodeId=83c1185636605, content=<a href='/topic/show?id=f32014428fc' target=_blank style='color:#2F92EE;'>#PNAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14428, encryptionId=f32014428fc, topicName=PNAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Wed Jan 01 09:27:00 CST 2020, time=2020-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1048288, encodeId=9f16104828831, content=什么时候有懒人用的减肥神药?, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Sun Dec 01 18:27:00 CST 2019, time=2019-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376082, encodeId=42b33e608258, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Sun Dec 01 16:47:46 CST 2019, time=2019-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376081, encodeId=47b03e60818b, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Sun Dec 01 16:47:43 CST 2019, time=2019-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376080, encodeId=68a73e60805d, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Sun Dec 01 16:47:40 CST 2019, time=2019-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376079, encodeId=5ea53e607907, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Sun Dec 01 16:47:35 CST 2019, time=2019-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376078, encodeId=f59d3e6078fd, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Sun Dec 01 16:47:31 CST 2019, time=2019-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376077, encodeId=00603e6077be, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Sun Dec 01 16:47:29 CST 2019, time=2019-12-01, status=1, ipAttribution=)]
    2019-12-01 14794e5bm67(暂无昵称)

    学习了,谢谢分享

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1981155, encodeId=513d198115519, content=<a href='/topic/show?id=1bbe38225a4' target=_blank style='color:#2F92EE;'>#口服液#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38225, encryptionId=1bbe38225a4, topicName=口服液)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=856b247, createdName=songbq, createdTime=Sat Mar 07 23:27:00 CST 2020, time=2020-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1856366, encodeId=83c1185636605, content=<a href='/topic/show?id=f32014428fc' target=_blank style='color:#2F92EE;'>#PNAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14428, encryptionId=f32014428fc, topicName=PNAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Wed Jan 01 09:27:00 CST 2020, time=2020-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1048288, encodeId=9f16104828831, content=什么时候有懒人用的减肥神药?, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Sun Dec 01 18:27:00 CST 2019, time=2019-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376082, encodeId=42b33e608258, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Sun Dec 01 16:47:46 CST 2019, time=2019-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376081, encodeId=47b03e60818b, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Sun Dec 01 16:47:43 CST 2019, time=2019-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376080, encodeId=68a73e60805d, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Sun Dec 01 16:47:40 CST 2019, time=2019-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376079, encodeId=5ea53e607907, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Sun Dec 01 16:47:35 CST 2019, time=2019-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376078, encodeId=f59d3e6078fd, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Sun Dec 01 16:47:31 CST 2019, time=2019-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376077, encodeId=00603e6077be, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Sun Dec 01 16:47:29 CST 2019, time=2019-12-01, status=1, ipAttribution=)]
    2019-12-01 14794e5bm67(暂无昵称)

    学习了,谢谢分享

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1981155, encodeId=513d198115519, content=<a href='/topic/show?id=1bbe38225a4' target=_blank style='color:#2F92EE;'>#口服液#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38225, encryptionId=1bbe38225a4, topicName=口服液)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=856b247, createdName=songbq, createdTime=Sat Mar 07 23:27:00 CST 2020, time=2020-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1856366, encodeId=83c1185636605, content=<a href='/topic/show?id=f32014428fc' target=_blank style='color:#2F92EE;'>#PNAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14428, encryptionId=f32014428fc, topicName=PNAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Wed Jan 01 09:27:00 CST 2020, time=2020-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1048288, encodeId=9f16104828831, content=什么时候有懒人用的减肥神药?, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Sun Dec 01 18:27:00 CST 2019, time=2019-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376082, encodeId=42b33e608258, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Sun Dec 01 16:47:46 CST 2019, time=2019-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376081, encodeId=47b03e60818b, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Sun Dec 01 16:47:43 CST 2019, time=2019-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376080, encodeId=68a73e60805d, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Sun Dec 01 16:47:40 CST 2019, time=2019-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376079, encodeId=5ea53e607907, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Sun Dec 01 16:47:35 CST 2019, time=2019-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376078, encodeId=f59d3e6078fd, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Sun Dec 01 16:47:31 CST 2019, time=2019-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376077, encodeId=00603e6077be, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Sun Dec 01 16:47:29 CST 2019, time=2019-12-01, status=1, ipAttribution=)]
    2019-12-01 14794e5bm67(暂无昵称)

    学习了,谢谢分享

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1981155, encodeId=513d198115519, content=<a href='/topic/show?id=1bbe38225a4' target=_blank style='color:#2F92EE;'>#口服液#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38225, encryptionId=1bbe38225a4, topicName=口服液)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=856b247, createdName=songbq, createdTime=Sat Mar 07 23:27:00 CST 2020, time=2020-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1856366, encodeId=83c1185636605, content=<a href='/topic/show?id=f32014428fc' target=_blank style='color:#2F92EE;'>#PNAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14428, encryptionId=f32014428fc, topicName=PNAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Wed Jan 01 09:27:00 CST 2020, time=2020-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1048288, encodeId=9f16104828831, content=什么时候有懒人用的减肥神药?, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Sun Dec 01 18:27:00 CST 2019, time=2019-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376082, encodeId=42b33e608258, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Sun Dec 01 16:47:46 CST 2019, time=2019-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376081, encodeId=47b03e60818b, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Sun Dec 01 16:47:43 CST 2019, time=2019-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376080, encodeId=68a73e60805d, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Sun Dec 01 16:47:40 CST 2019, time=2019-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376079, encodeId=5ea53e607907, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Sun Dec 01 16:47:35 CST 2019, time=2019-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376078, encodeId=f59d3e6078fd, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Sun Dec 01 16:47:31 CST 2019, time=2019-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376077, encodeId=00603e6077be, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Sun Dec 01 16:47:29 CST 2019, time=2019-12-01, status=1, ipAttribution=)]
    2019-12-01 14794e5bm67(暂无昵称)

    学习了,谢谢分享

    0

相关资讯

Schizophr Res:精神分裂症共病肥胖与认知功能损伤呈负相关

肥胖是精神分裂症中一种典型的代谢综合征,荟萃分析报告了精神分裂症合并肥胖的风险升高,肥胖发病率是一般人群的1.5-4倍。

AHA2019丨减肥手术可改善肥胖患者的脑血管结局

11月16~18日,2019美国心脏协会(AHA)科学年会在费城召开。除最新研究外,口头报告也备受瞩目,其中,最佳卒中摘要专场的两项研究引起参会者的关注。肥胖患者的减肥手术和脑血管结局与肥胖有关的代谢变化可导致脑血管疾病的发展,减肥手术是实现肥胖患者体重和代谢状况可靠改善的有效手段。尽管如此,其在长期减少脑血管发病率方面的有效性仍不清楚。Maddalena Ardissino等研究者公布的一项研究

Circulation:青春期肥胖显著增加成年后罹患心肌病的风险

心肌病是年轻人心衰的一种常见且日益增加的原因,但与心肌病风险相关的可改变的生活方式因素尚未在年轻人中进行充分的研究。肥胖是公认的早期心力衰竭的预测因素。青少年时期肥胖与成年后罹患心肌病是否存在相关性?本研究是一个国家范围的前瞻性的队列研究,共纳入了于1969年-2005年期间服兵役的1 668 893位青少年男生(平均18.3岁)。起始时,记录体重指数(BMI)、血压和疾病,以及体能和肌肉强度的测

Arthritis Rheumatol:饮食引起肥胖、代谢失衡和骨关节炎的代际传播

肥胖和骨关节炎(OA)是影响全球数百万人的两个重要公共卫生问题。尽管父母肥胖会影响儿​​童对癌症或糖尿病等疾病的易感性,但人们对诸如OA等肌肉骨骼疾病的跨代影响却知之甚少。   研究了高脂饮食或对照饮食喂养小鼠的第一代(F1)和第二代(F2)后代的代谢表型和OA易感性(每个性别/每种饮食n=10-16)。通过使内侧半月板不稳定来诱导OA。通过组织学确定OA、滑膜炎和脂肪组织炎

Heart:体重的增加会增加房颤的发生风险

全球范围内肥胖的发病率逐渐上升,由于肥胖是房颤的危险因素,这也可以部分解释房颤的发病率也呈逐渐上升。本次荟萃分析研究的目的旨在评估体重的变化对房颤的影响。本研究对MEDLINE, Embase, Pubmed, Web of Science, Cochrane Central Register of Controlled Trials, Database of Abstracts of Revie

AHA2019丨肥胖患者是否能应用DOACs?

近年来,肥胖在全球范围内广泛流行且发病呈增加趋势。研究发现,肥胖会对药物代谢产生影响。那么,肥胖对于临床实践中直接口服抗凝药(DOACs)的选择有何影响?肥胖患者是否应选择用DOACs?在AHA 2019科学年会上,Karlyn Martin教授汇总各种相关研究的数据就这一问题进行了深入解析。